Compare Stocks: FBLG, IMMP, CELU, and TIL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELU Celularity	$1.69 +0.4%	$0.90	$0.56 ▼ $2.55	$48.78M	0.79	1.55 million shs	62,662 shs
FBLG FibroBiologics	$1.81 +0.1%	$1.07	$0.62 ▼ $12.40	$11.97M	1.65	262,748 shs	42,275 shs
IMMP Prima BioMed	$0.36 -0.8%	$0.40	$0.29 ▼ $3.53	$53.35M	2.21	5.59 million shs	33,205 shs
TIL Instil Bio	$7.64 +0.8%	$7.49	$5.67 ▼ $28.43	$51.81M	1.91	54,007 shs	1,376 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELU Celularity	0.00%	-9.19%	+139.76%	+144.01%	-30.29%
FBLG FibroBiologics	0.00%	+5.23%	+85.41%	+94.62%	-84.24%
IMMP Prima BioMed	0.00%	-0.30%	-5.42%	-1.08%	-77.88%
TIL Instil Bio	0.00%	-0.39%	+2.29%	-5.49%	-75.94%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELU Celularity	$1.69 +0.4%	$0.90	$0.56 ▼ $2.55	$48.78M	0.79	1.55 million shs	62,662 shs
FBLG FibroBiologics	$1.81 +0.1%	$1.07	$0.62 ▼ $12.40	$11.97M	1.65	262,748 shs	42,275 shs
IMMP Prima BioMed	$0.36 -0.8%	$0.40	$0.29 ▼ $3.53	$53.35M	2.21	5.59 million shs	33,205 shs
TIL Instil Bio	$7.64 +0.8%	$7.49	$5.67 ▼ $28.43	$51.81M	1.91	54,007 shs	1,376 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELU Celularity	0.00%	-9.19%	+139.76%	+144.01%	-30.29%
FBLG FibroBiologics	0.00%	+5.23%	+85.41%	+94.62%	-84.24%
IMMP Prima BioMed	0.00%	-0.30%	-5.42%	-1.08%	-77.88%
TIL Instil Bio	0.00%	-0.39%	+2.29%	-5.49%	-75.94%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CELU Celularity	2.00	Hold	$6.00	255.87% Upside
FBLG FibroBiologics	1.80	Reduce	$73.00	3,930.92% Upside
IMMP Prima BioMed	2.00	Hold	$5.50	1,419.34% Upside
TIL Instil Bio	1.67	Reduce	$66.00	763.65% Upside

Current Analyst Ratings Breakdown

Latest FBLG, IMMP, CELU, and TIL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	FBLG FibroBiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
9/2/2026	TIL Instil Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	CELU Celularity	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/20/2026	FBLG FibroBiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
8/19/2026	TIL Instil Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/5/2026	CELU Celularity	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/4/2026	FBLG FibroBiologics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00 ➝ $6.00
8/4/2026	FBLG FibroBiologics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Underperform
7/31/2026	TIL Instil Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/24/2026	FBLG FibroBiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/16/2026	TIL Instil Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CELU Celularity	$26.55M	1.84	N/A	N/A	($1.32) per share	-1.28
FBLG FibroBiologics	N/A	N/A	N/A	N/A	$1.85 per share	N/A
IMMP Prima BioMed	$16.40M	3.25	N/A	N/A	$0.28 per share	1.29
TIL Instil Bio	N/A	N/A	N/A	N/A	$16.79 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CELU Celularity	-$91.72M	-$3.33	N/A	N/A	N/A	-345.45%	N/A	-77.94%	11/13/2026 (Estimated)
FBLG FibroBiologics	-$18.65M	-$5.19	N/A	N/A	N/A	N/A	-536.78%	-225.12%	10/30/2026 (Estimated)
IMMP Prima BioMed	-$53.82M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	-$71.37M	-$4.47	N/A	N/A	N/A	N/A	-26.78%	-14.89%	11/16/2026 (Estimated)

Latest FBLG, IMMP, CELU, and TIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	TIL Instil Bio	-$0.35	-$0.63	-$0.28	-$0.63	N/A	N/A
7/31/2026	Q2 2026	FBLG FibroBiologics	-$0.93	-$0.66	+$0.27	-$0.66	N/A	N/A
7/30/2026	Q4 2026	IMMP Prima BioMed	N/A	-$0.09	N/A	-$0.0850	N/A	$3.68 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CELU Celularity	N/A	N/A	N/A	N/A	N/A
FBLG FibroBiologics	N/A	N/A	N/A	N/A	N/A
IMMP Prima BioMed	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CELU Celularity	N/A	0.15	0.15
FBLG FibroBiologics	N/A	2.64	2.64
IMMP Prima BioMed	N/A	5.69	N/A
TIL Instil Bio	0.79	21.67	21.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CELU Celularity	19.02%
FBLG FibroBiologics	N/A
IMMP Prima BioMed	2.32%
TIL Instil Bio	60.56%

Insider Ownership

Company	Insider Ownership
CELU Celularity	17.30%
FBLG FibroBiologics	7.30%
IMMP Prima BioMed	3.07%
TIL Instil Bio	47.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CELU Celularity	220	28.95 million	23.94 million	Optionable
FBLG FibroBiologics	10	6.66 million	6.17 million	N/A
IMMP Prima BioMed	2,021	147.37 million	142.85 million	Optionable
TIL Instil Bio	410	6.78 million	3.59 million	No Data

FBLG, IMMP, CELU, and TIL Headlines

Recent News About These Companies

5 Biotech Stocks Worth Adding to Your Portfolio Now

August 26, 2026 | zacks.com

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 13, 2026 | globenewswire.com

Iovance: The Worst May Be Behind This TIL Pioneer (Upgrading To Buy)

July 16, 2026 | seekingalpha.com

Instil Bio Shareholders Back Directors and Auditor at Meeting

June 11, 2026 | tipranks.com

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 15, 2026 | globenewswire.com

Instil Bio (TIL) Price Target Increased by 24.53% to 67.32

April 9, 2026 | msn.com

Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 27, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

February 12, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

February 3, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 29, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio,

January 27, 2026 | bakersfield.comB

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 27, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 22, 2026 | prnewswire.com

TIL ALERT: Ongoing Investigation Into Instil Bio, Inc. - Contact Levi & Korsinsky

January 20, 2026 | newsfilecorp.comN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 20, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 15, 2026 | prnewswire.com

Instil Bio (TIL) Price Target Decreased by 45.17% to 53.55

January 14, 2026 | msn.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 13, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 8, 2026 | prnewswire.com

HC Wainwright & Co. downgrades Instil Bio (TIL)

January 8, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG, IMMP, CELU, and TIL Company Descriptions

Celularity NASDAQ:CELU

$1.69 +0.01 (+0.36%)

As of 10:25 AM Eastern

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

FibroBiologics NASDAQ:FBLG

$1.81 +0.00 (+0.06%)

As of 10:26 AM Eastern

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

Prima BioMed NASDAQ:IMMP

$0.36 0.00 (-0.79%)

As of 10:25 AM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Instil Bio NASDAQ:TIL

$7.64 +0.06 (+0.82%)

As of 10:17 AM Eastern

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FBLG, IMMP, CELU, and TIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FBLG, IMMP, CELU, and TIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FBLG, IMMP, CELU, and TIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG, IMMP, CELU, and TIL Company Descriptions

Celularity NASDAQ:CELU

FibroBiologics NASDAQ:FBLG

Prima BioMed NASDAQ:IMMP

Instil Bio NASDAQ:TIL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FBLG, IMMP, CELU, and TIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FBLG, IMMP, CELU, and TIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FBLG, IMMP, CELU, and TIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG, IMMP, CELU, and TIL Company Descriptions

Celularity NASDAQ:CELU

FibroBiologics NASDAQ:FBLG

Prima BioMed NASDAQ:IMMP

Instil Bio NASDAQ:TIL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools